reason report
take step back put best foot forward swap
bottom line market close provid compani
updat follow end phase meet fda
lead program ulcer coliti uc result
fda request dose-rang work
enter phase decid switch
back-up higher potenc better
target engag preclin studi although switch may
introduc risk sinc preclin drug candid
test human believ swap could help
deliv superior clinic efficaci increasingli competit
program adjust model accordingli
updat project timelin includ push back launch
lower pt
potent peptid preclin studi like
oral gi-restrict integrin
antagonist although propel data eventu posit
protact re-analysi data caus error contract
research organ cro link termin trial result
small data set total result fda consid
data suffici justifi entri registr phase studi
expect link henc make best situat
revert back-up potent preclin
studi develop minim loss time
rel new requir fda conduct phase
dose-rang studi order advanc although
overal cadenc delay could potenti deliv higher
efficaci break efficaci ceil shown ibd drug
includ highest dose test mg link
preclin data encourag demonstr higher
potenc potent cell adhes assay longer
receptor occup circul cell lower dose
improv efficaci lower colon weight/length better histopatholog
believ combin higher potenc higher dose
dose rang mg vs mg
could ultim translat superior efficaci although take
time see
dcf analysi discount rate
termin growth rate
gener net cash dilut share outstand
base estim
year price history/av daili volume mil
creat bluematrix
compani inform leerink partner llc research
revenu report ep
pleas refer page import disclosur price chart analyst certif
updat model reflect ptgx new timelin
guidanc push back potenti mileston
payment op addit
probability-adjust mileston payment receiv
respect
push market launch
previous launch better reflect
guidanc maintain po due
encourag preclin data valuabl learn
valid target compani improv cash
runway guidanc includ potenti mileston
payment
protagonist clinical-stag biopharmaceut compani proprietari technolog platform
focus discov develop first-in-class peptid drug specif target
biolog pathway also target current market inject antibodi drug protagonist
oral peptid offer target deliveri potenti improv safeti due minim system
exposur along conveni anticip increas complianc due oral deliveri
lead product candid formerli potenti
transform exist treatment paradigm irrit bowel diseas ibd umbrella term
gi disord ulcer coliti uc crohn diseas cd
integrin pathway consid one specif biolog mechan ibd
integrin antagonist design block migrat inflammatori cell gi tissu
hallmark ibd potenti first-in-class oral
integrin-specif antagonist peptid product candid moderate-to-sever uc patient
propel studi data discuss fda compani strateg
decid switch back-up drug candid demonstr superior
vivo efficaci target engag expect initi
integrin also target entyvio vedolizumab takeda current market infus
antibodi drug rapidli grow use integrin antagonist class
may well posit share
protagonist second lead product candid potenti first-in-class oral
receptor antagonist develop initi moderate-to-sever cd
antagonist aim offer improv specif antibodi
stelara approv psoriasi late-stag develop uc shown
promis result maintain clinic remiss moder sever cd patient although
partnership janssen/jnj cap upsid stem asset clinic expertis
commerci infrastructur could enhanc drug commerci success long-run
protagonist also advanc inject hepcidin mimet iron overload
disord gener compel proof biolog data thalassem mice
show follow treatment hemoglobin level increas spleen/ bodi weight
ratio decreas expect initi phase patient beta-thalassemia
pt base discount cash flow dcf analysi assum
discount rate termin growth rate estim probabl
launch assum peak penetr biolog refractori uc patient peak
penetr first-lin treatment uc patient lead ww risk-adjust peak revenu
also current model probability-weight peak revenu
royalti partnership janssen
risk includ potenti disappoint clinic data regulatori setback commerci
shortfal amend partnership janssen/jnj asset
amort janssen
chang fair valu pref stock wl
net incom loss attribut common
chang
oper
invest
redempt purchas secur
financ
sec file compani report leerink partner research
forma estim ipo price
flow oper
flow invest
compani report leerink partner research
oral peptid gi ibd
report leerink partner research
phase initi pt beta-thalassemia
phase initi readout pt beta-thalassemia
phase top-line result pt beta-thalassemia
